Shenzhen, China, 26 May 2022-- Snibe has received the CE List A Certificate for 5 MAGLUMI? CLIA immunoassays
of Hepatitis B virus (HBV) detection, covering Anti-HBc IgM, Anti-HBs, HBeAg,
Anti-HBe, and anti-HBC. Up to now, 6 CLIA immunoassays for HBV detection have
all obtained CE List A Certificate, besides the MAGLUMI? HBsAg (CLIA) Assay.
Recently, Snibe receives the CE mark for
its RapisafeTM SARS-CoV-2 Ag test (Colloidal Gold), which further
confirmed that the quality of our Self-Testing kits is in line with
international standards.
From August 29th to 31st, 2019, the 15th National Congress of Laboratory Medicine (NCLM 2019), hosted by Chinese Medical Association and Chinese Society of Laboratory Medicine, was held at Suzhou International Expo Centre.
Aiming to further explore the clinical application of serological indicators in early screening and diagnosis of HCC, the School of Basic Medical Sciences Peking University (SBMS, PKU) held an online meeting on June 25, 2022, to officially announce the launch of the project: Multicenter Study in Evaluating the Combination of Multiple Indicators in HCC Screening. Snibe is the exclusive industry supporter.
Snibe
received the CE certificate (List A) for MAGLUMI? HBsAg (CLIA) assay On March 11,
2022. It further proves the high reliability of the quality and performance of
Snibe products, as well as a verification of Snibe’s leading position in the
field of chemiluminescence.
On December 15, 2020, Snibe's MAGLUMI? TSH assay and MAGLUMI? CA 19-9 assay were certified the IVDR CE Certification by TüV SüD Product Service GmbH an EU Notified Body, making Snibe one of the first IVDR CE-certified manufacturers for CLIA products in Asia.